F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.

The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.

Patient organization exploring development of a multi-stakeholder forum on real world evidence that, among other things, could address research questions posed by the Centers for Medicare and Medicaid Services in its national coverage determination for Alzheimer’s drugs.

NAD attorneys didn’t act on P&G challenge to i-Health labeling Culturelle IBS Complete Support as medical food. They agreed with P&G’s challenge against claims Royal DSM subsidiary used on packaging and online, including “Living with IBS is difficult, taking Culturelle IBS complete support to help manage symptoms is easy.”